These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 14655082)

  • 21. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
    Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
    Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense oligonucleotide therapy for urologic tumors.
    Kausch I; Böhle A
    Curr Urol Rep; 2003 Feb; 4(1):60-9. PubMed ID: 12537941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense DNAs as targeted therapeutics for cancer: no longer a dream.
    Cho-Chung YS
    Curr Opin Investig Drugs; 2002 Jun; 3(6):934-9. PubMed ID: 12137417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro.
    Hammamieh R; Chakraborty N; Das R; Jett M
    J Exp Ther Oncol; 2004 Oct; 4(3):195-202. PubMed ID: 15724839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
    Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
    Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antisense oligonucleotide derivatives as gene-targeted drugs.
    Knorre DG; Vlassov VV
    Biomed Sci; 1990 Apr; 1(4):334-43. PubMed ID: 1723003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I
    Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prospects for antisense therapy].
    Maekawa T
    Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapy of human laryngeal squamous cell carcinoma in vitro by antisense oligonucleotides directed against telomerase reverse transcriptase mRNA.
    Tao Z; Chen S; Wu Z; Xiao B; Liu J; Hou W
    J Laryngol Otol; 2005 Feb; 119(2):92-6. PubMed ID: 15829059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological principles and clinical development of prostate cancer gene therapy.
    Sanda MG
    Semin Urol Oncol; 1997 Feb; 15(1):43-55. PubMed ID: 9050139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular therapy of human neuroblastoma cells using Auger electrons of 111In-labeled N-myc antisense oligonucleotides.
    Watanabe N; Sawai H; Ogihara-Umeda I; Tanada S; Kim EE; Yonekura Y; Sasaki Y
    J Nucl Med; 2006 Oct; 47(10):1670-7. PubMed ID: 17015904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.